JP7569313B2 - Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法 - Google Patents

Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法 Download PDF

Info

Publication number
JP7569313B2
JP7569313B2 JP2021522096A JP2021522096A JP7569313B2 JP 7569313 B2 JP7569313 B2 JP 7569313B2 JP 2021522096 A JP2021522096 A JP 2021522096A JP 2021522096 A JP2021522096 A JP 2021522096A JP 7569313 B2 JP7569313 B2 JP 7569313B2
Authority
JP
Japan
Prior art keywords
tcr
amino acid
cancer
eso
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505679A5 (enExample
JP2022505679A (ja
Inventor
ロバート バブ，
ナタリー バウワーマン，
ガン チェン，
ケイガン ギュラー，
ジョアンナ ハンセン，
ウェン－イー リー，
トーマス ミアガー，
デイビッド スー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022505679A publication Critical patent/JP2022505679A/ja
Publication of JP2022505679A5 publication Critical patent/JP2022505679A5/ja
Application granted granted Critical
Publication of JP7569313B2 publication Critical patent/JP7569313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2021522096A 2018-10-23 2019-10-23 Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法 Active JP7569313B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749194P 2018-10-23 2018-10-23
US62/749,194 2018-10-23
PCT/US2019/057543 WO2020086647A1 (en) 2018-10-23 2019-10-23 Ny-eso-1 t cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022505679A JP2022505679A (ja) 2022-01-14
JP2022505679A5 JP2022505679A5 (enExample) 2022-10-31
JP7569313B2 true JP7569313B2 (ja) 2024-10-17

Family

ID=68582342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522096A Active JP7569313B2 (ja) 2018-10-23 2019-10-23 Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法

Country Status (10)

Country Link
US (1) US12466870B2 (enExample)
EP (1) EP3870602A1 (enExample)
JP (1) JP7569313B2 (enExample)
KR (1) KR102933479B1 (enExample)
CN (1) CN113454110B (enExample)
AU (2) AU2019364367B2 (enExample)
CA (1) CA3117539A1 (enExample)
EA (1) EA202191107A1 (enExample)
MA (1) MA53981A (enExample)
WO (1) WO2020086647A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
CN113454110B (zh) 2018-10-23 2024-07-02 里珍纳龙药品有限公司 Ny-eso-1 t细胞受体和其使用方法
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021297458B2 (en) * 2020-06-25 2026-06-18 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP7526079B2 (ja) * 2020-11-13 2024-07-31 Ykk Ap株式会社 樹脂枠の製造方法、樹脂枠
TW202246511A (zh) * 2021-02-25 2022-12-01 美商萊爾免疫藥物股份有限公司 靶向ny-eso-1之增強免疫細胞療法
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN113912701B (zh) * 2021-10-14 2024-07-19 深圳大学总医院 Tcr及其在诊断/治疗中的应用
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023114433A1 (en) * 2021-12-15 2023-06-22 3T Biosciences, Inc. Methods and systems for assessing immune cell receptors and antigens
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US12584107B2 (en) 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230287448A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512435A (ja) 2013-03-13 2016-04-28 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
JP2016523268A (ja) 2013-06-26 2016-08-08 グアンツォウ シャンスエ ファーマシューティカル カンパニー リミテッドＧｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ． Ｌｔｄ 高安定性のｔ細胞受容体およびその製法と使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2835200T3 (es) * 2012-05-22 2021-06-22 Us Health Uso médico de células que comprenden receptores de células T anti-NY-ESO-1
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
CN105985427A (zh) * 2015-02-06 2016-10-05 广州市香雪制药股份有限公司 高亲和力ny-eso t细胞受体
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CN106188275A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别ny-eso-1抗原短肽的t细胞受体
KR20180043800A (ko) * 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
CN106432475B (zh) * 2015-10-19 2018-06-01 广东香雪精准医疗技术有限公司 高亲和力ny-eso t细胞受体
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
AU2018207172B2 (en) * 2017-01-13 2023-10-12 Mink Therapeutics, Inc. T cell receptors that bind to NY-ESO-1 and methods of use thereof
CN108456247A (zh) * 2017-02-20 2018-08-28 上海恒润达生生物科技有限公司 靶向ny-eso-1的t细胞受体及其用途
CN113454110B (zh) 2018-10-23 2024-07-02 里珍纳龙药品有限公司 Ny-eso-1 t细胞受体和其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512435A (ja) 2013-03-13 2016-04-28 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
JP2016523268A (ja) 2013-06-26 2016-08-08 グアンツォウ シャンスエ ファーマシューティカル カンパニー リミテッドＧｕａｎｇｚｈｏｕ Ｘｉａｎｇｘｕｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ． Ｌｔｄ 高安定性のｔ細胞受容体およびその製法と使用

Also Published As

Publication number Publication date
US20210403527A1 (en) 2021-12-30
MA53981A (fr) 2021-09-01
WO2020086647A8 (en) 2020-05-28
WO2020086647A1 (en) 2020-04-30
EA202191107A1 (ru) 2021-09-17
US12466870B2 (en) 2025-11-11
CN113454110A (zh) 2021-09-28
AU2019364367A1 (en) 2021-05-27
KR102933479B1 (ko) 2026-03-04
AU2019364367B2 (en) 2025-02-27
AU2025203827A1 (en) 2025-06-12
JP2022505679A (ja) 2022-01-14
CA3117539A1 (en) 2020-04-30
KR20210093908A (ko) 2021-07-28
CN113454110B (zh) 2024-07-02
EP3870602A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
US12466870B2 (en) NY-ESO-1 T cell receptors and methods of use thereof
JP7730765B2 (ja) Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025092600A (ja) 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法
US12600793B2 (en) Chimeric antigen receptors with MAGE-A4 specificity and uses thereof
US20160083449A1 (en) T cell immunotherapy specific for wt-1
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2019080568A (ja) 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
EA048202B1 (ru) T-клеточные рецепторы ny-eso-1 и способы их применения
EA048220B1 (ru) Т-клеточные рецепторы к предпочтительно экспрессируемому антигену меланомы (prame) и способы их применения
EA048440B1 (ru) T-клеточные рецепторы к mage-a4 и способы их применения
EA047914B1 (ru) Химерные антигенные рецепторы со специфичностью к mage-a4 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241004

R150 Certificate of patent or registration of utility model

Ref document number: 7569313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150